Tseng S, Pak G, Washenik K, Pomeranz M K, Shupack J L
Ronald O. Perelman Department of Dermatology, New York University Medical Center, NY 10016, USA.
J Am Acad Dermatol. 1996 Dec;35(6):969-79. doi: 10.1016/s0190-9622(96)90122-x.
Thalidomide, a hypnosedative drug introduced in the 1950s, has been used in a variety of dermatologic conditions during the past few decades. Although originally withdrawn from the world market on discovery of its teratogenic effect, it has since been selectively reintroduced for use in various disorders thought to have an autoimmune or inflammatory basis. A review of the literature focused on clinical uses of thalidomide in the treatment of dermatologic diseases was performed. Diseases for which thalidomide has been found effective include erythema nodosum leprosum, prurigo nodularis, actinic prurigo, discoid lupus erythematosus, aphthous stomatitis, Behçet's syndrome, and graft-versus-host disease. Side effects such as teratogenicity and peripheral neuropathy remain its limiting factor. Thalidomide is a useful addition to the therapeutic armamentarium for treatment-resistant dermatoses as long as proper vigilance for adverse effects is maintained.
沙利度胺是20世纪50年代推出的一种催眠镇静药物,在过去几十年中已被用于多种皮肤病。尽管最初因其致畸作用而退出世界市场,但此后已被选择性地重新引入,用于治疗各种被认为具有自身免疫或炎症基础的疾病。我们对聚焦于沙利度胺治疗皮肤病临床应用的文献进行了综述。已发现沙利度胺有效的疾病包括麻风结节性红斑、结节性痒疹、光化性痒疹、盘状红斑狼疮、阿弗他口炎、白塞综合征和移植物抗宿主病。致畸性和周围神经病变等副作用仍然是其限制因素。只要对不良反应保持适当警惕,沙利度胺对于治疗抵抗性皮肤病来说是治疗手段中的一项有用补充。